Australia's most trusted
source of pharma news
Posted 27 November 2024 AM
A multinational team of researchers co-led by the Garvan Institute of Medical Research say that they've found an avenue for fine-tuning cancer immunotherapies after taking a deep dive into the 'yin and yang' nature of PD-1 inhibitors.
Immune checkpoint inhibitor therapies, such as MSD's Keytruda and BMS' Opdivo have "revolutionised cancer treatment" by allowing T cells to attack tumours and cancer cells more effectively, according to Head of the Immunology and Immunodeficiency Lab at Garvan Professor Stuart Tangye.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.